Estudio de fase 1/3, doble ciego, aleatorizado, con control activo yde grupos paralelos para comparar la eficacia, la farmacocinética, la farmacodinámicay la seguridad de CT-P53 y Ocrevus en pacientes con esclerosis múltiple remitenterecurrente

• Protocol code: CT-P53 3.1
• EudraCT code: No aplica
• Research group: Clinical Neuroimmunology
• Service: Neuroimmunology
• Principal investigator:  Montalban Gairín, Xavier
• Pathology: Malalties del sistema nerviós
• Phase: Fase III
• Status: Recruiting volunteers

Ensayo fase III, aleatorizado, doble ciego para evaluar el efecto de balcinrenona/dapagliflozina, en comparación con dapagliflozina, sobre el riesgo de eventos de insuficiencia cardiaca y muerte cardiovascular en pacientes con insuficiencia cardíaca y función renal alterada

• Protocol code: D6402C00012
• EudraCT code: No aplica
• Research group: Cardiovascular Diseases
• Service: Cardiology
• Principal investigator:  Méndez Fernández, Ana Belén
• Pathology: Malalties del sistema circulatori
• Phase: Fase III

ESTUDIO EN FASE IIIB SIN ENMASCARAMIENTO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DEL TRATAMIENTO CON LEBRIKIZUMAB EN ADULTOS Y ADOLESCENTES CON DERMATITIS ATÓPICA DE MODERADA A GRAVE.

• Protocol code: M-17923-34
• EudraCT code: No aplica
• Service: Dermatologia
• Principal investigator:  Aparicio Español, Gloria
• Pathology: Tumors
• Phase: Fase III
• Status: Recruiting volunteers

An Exploratory, Multicenter, Randomized, double-blind, placebo-controlled study evaluating the effect and safety of pitolisant in children and adolescents with Autism Spectrum Disorders.

• Protocol code: P21-01
• EudraCT code: _
• Research group: Psychiatry, Mental Health and Addictions
• Service: Psychiatry
• Principal investigator:  Gisbert Gustemps, Laura
• Pathology: Trastorns mentals i del comportament
• Phase: Fase II

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults with IgA Nephropathy

• Protocol code: CHK02-02
• EudraCT code: No aplica
• Research group: Nephrology and kidney transplantation
• Service: Nephrology
• Principal investigator:  Agraz Pamplona, Irene
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase III

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial toEvaluate the Neurological Effects of EryDex on subjects with Ataxia Telangiectasia

• Protocol code: IEDAT-04-2022
• EudraCT code: No aplica
• Research group: Therapeutics and Innovations in Neuropediatrics and other paediatric rare diseases
• Service: General Pediatrics and Specialties
• Principal investigator:  Gómez Andrés, David
• Pathology: Malalties del sistema nerviós
• Phase: Fase III
• Status: Recruiting volunteers

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 Over 21 Days Ambulatory Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease

• Protocol code: NMD670-02-0003
• EudraCT code: No aplica
• Research group: Peripheral Nervous System
• Service: Neurology
• Principal investigator:  Juntas Morales, Raul
• Pathology: Malalties del sistema nerviós
• Phase: Fase II

Effects of NNC0194-0499 alone and in combination with semaglutide, of semaglutide alone, and of cagrilintide alone and in combination with semaglutide on liver damage and alcohol use in people with alcohol-related liver disease

• Protocol code: NN9500-7730
• EudraCT code: No aplica
• Research group: Liver Diseases
• Service: Hepatology
• Principal investigator:  Ventura Cots, Meritxell
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase II
• Status: Recruiting volunteers

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect ofEDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults andAdolescents with Becker Muscular Dystrophy

• Protocol code: EDG-5506-201
• EudraCT code: No aplica
• Research group: Peripheral Nervous System
• Service: Neurology
• Principal investigator:  Juntas Morales, Raul
• Phase: Fase II
• Status: Recruiting volunteers